Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

On April 6, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that its Chairman and CEO, Dr. Amit Kumar, was recently featured in an interview on the Smart Money Circle program hosted by Adam Sarhan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the interview, Dr. Kumar discussed Anixa’s innovative approach to cancer treatment and prevention, with a particular focus on the Company’s advancing immunotherapy pipeline, including its breast cancer vaccine and ovarian cancer CAR-T therapy programs. Anixa’s breast cancer vaccine recently completed a Phase 1 clinical trial where it met primary endpoints and generated protocol-defined immune responses in 74% of participants. In addition, Anixa’s ovarian cancer CAR-T therapy, lira-cel, is exhibiting positive survival data in an ongoing Phase 1 clinical trial.

The full interview is available here: Smart Money Circle Interview.

(Press release, Anixa Biosciences, APR 6, 2026, View Source [SID1234664180])